A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy.
Brian H SantichSarah M ChealMahiuddin AhmedMichael R McDevittOuathek OuerfelliGuangbin YangDarren R VeachEdward K FungMitesh PatelDaniela Burnes VargasAiza A MalikHong-Fen GuoPat B ZanzonicoSebastien MonetteAdam O MichelCharles M RudinSteven M LarsonNai Kong V CheungPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The SADA-BsAb platform safely delivered large doses of radioisotopes to tumors and demonstrated no toxicities to the bone marrow, kidneys, or liver. Because of its modularity, SADA-BsAbs can be easily adapted to most tumor antigens, tumor types, or drug delivery approaches to improve therapeutic index and maximize the delivered dose.See related commentary by Capala and Kunos, p. 377.